FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295779301> ?p ?o ?g. }

• W4295779301 abstract "Abstract Objectives The aim of this analysis was to describe nirmatrelvir/ritonavir real-world effectiveness in preventing hospitalization among high-risk US COVID-19 patients during SARS-CoV-2 Omicron predominance. Design An ongoing population-based cohort study with retrospective and prospective collection of electronic healthcare data in the United States. Methods Data for this analysis were collected from the US Optum® de-identified COVID-19 Electronic Health Record (EHR) dataset during December 22, 2021−June 8, 2022. Key eligibility criteria for inclusion in the database analysis were ≥12-years-old; positive SARS-CoV-2 test, COVID-19 diagnosis, or nirmatrelvir/ritonavir prescription; and high risk of severe COVID-19 based on demographic/clinical characteristics. Potential confounders between groups were balanced using propensity score matching (PSM). Immortal time bias was addressed. Outcome measures Hospitalization rates within 30 (primary analysis) or 15 (sensitivity analysis) days from COVID-19 diagnosis overall and within subgroups were evaluated. Results Before PSM, the nirmatrelvir/ritonavir group (n=2811) was less racially diverse, older, and had higher COVID-19 vaccination rates and a greater number of comorbidities than the non-nirmatrelvir/ritonavir group (n=194,542). Baseline characteristics were well balanced across groups (n=2808 and n=10,849, respectively) after PSM. Incidence of hospitalization (95% CI) within 30 days was 1.21% (0.84%−1.69%) for the nirmatrelvir/ritonavir group and 6.94% (6.03%−7.94%) for the non-nirmatrelvir/ritonavir group, with a hazard ratio (95% CI) of 0.16 (0.11−0.22; 84% relative risk reduction). Incidence within 15 days was 0.78% (0.49%−1.18%) for the nirmatrelvir/ritonavir group and 6.54% (5.65%−7.52%) for the non-nirmatrelvir/ritonavir group; hazard ratio 0.11 (0.07−0.17; 89% relative risk reduction). Nirmatrelvir/ritonavir was effective in African American patients (hazard ratio, 0.35 [0.15−0.83]; 65% relative risk reduction). Relative risk reductions were comparable with overall results across ages and among vaccinated patients. Conclusions Real-world nirmatrelvir/ritonavir effectiveness against hospitalization during the Omicron era supports EPIC-HR efficacy among high-risk patients. Future research should confirm these early real-world results and address limitations." @default.
• W4295779301 created "2022-09-15" @default.
• W4295779301 creator A5000786302 @default.
• W4295779301 creator A5002615180 @default.
• W4295779301 creator A5008375300 @default.
• W4295779301 creator A5018801440 @default.
• W4295779301 creator A5040885700 @default.
• W4295779301 creator A5046204043 @default.
• W4295779301 creator A5058966531 @default.
• W4295779301 creator A5061310691 @default.
• W4295779301 creator A5072861069 @default.
• W4295779301 date "2022-09-14" @default.
• W4295779301 modified "2023-10-16" @default.
• W4295779301 title "Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization Among Patients With COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study" @default.
• W4295779301 cites W2026656096 @default.
• W4295779301 cites W2036193982 @default.
• W4295779301 cites W2161515661 @default.
• W4295779301 cites W2560688864 @default.
• W4295779301 cites W2602904671 @default.
• W4295779301 cites W2904964912 @default.
• W4295779301 cites W3026764413 @default.
• W4295779301 cites W3036402194 @default.
• W4295779301 cites W3087151262 @default.
• W4295779301 cites W3116910832 @default.
• W4295779301 cites W3128376114 @default.
• W4295779301 cites W3159647759 @default.
• W4295779301 cites W3180039641 @default.
• W4295779301 cites W3189646261 @default.
• W4295779301 cites W3193213823 @default.
• W4295779301 cites W3213286842 @default.
• W4295779301 cites W4207020509 @default.
• W4295779301 cites W4210353860 @default.
• W4295779301 cites W4214775501 @default.
• W4295779301 cites W4221059015 @default.
• W4295779301 cites W4221117156 @default.
• W4295779301 cites W4225338642 @default.
• W4295779301 cites W4226236384 @default.
• W4295779301 cites W4281621145 @default.
• W4295779301 cites W4281988270 @default.
• W4295779301 cites W4282983857 @default.
• W4295779301 cites W4283018955 @default.
• W4295779301 cites W4283258331 @default.
• W4295779301 cites W4293198902 @default.
• W4295779301 doi "https://doi.org/10.1101/2022.09.13.22279908" @default.
• W4295779301 hasPublicationYear "2022" @default.
• W4295779301 type Work @default.
• W4295779301 citedByCount "7" @default.
• W4295779301 countsByYear W42957793012022 @default.
• W4295779301 countsByYear W42957793012023 @default.
• W4295779301 crossrefType "posted-content" @default.
• W4295779301 hasAuthorship W4295779301A5000786302 @default.
• W4295779301 hasAuthorship W4295779301A5002615180 @default.
• W4295779301 hasAuthorship W4295779301A5008375300 @default.
• W4295779301 hasAuthorship W4295779301A5018801440 @default.
• W4295779301 hasAuthorship W4295779301A5040885700 @default.
• W4295779301 hasAuthorship W4295779301A5046204043 @default.
• W4295779301 hasAuthorship W4295779301A5058966531 @default.
• W4295779301 hasAuthorship W4295779301A5061310691 @default.
• W4295779301 hasAuthorship W4295779301A5072861069 @default.
• W4295779301 hasBestOaLocation W42957793011 @default.
• W4295779301 hasConcept C120665830 @default.
• W4295779301 hasConcept C121332964 @default.
• W4295779301 hasConcept C126322002 @default.
• W4295779301 hasConcept C142462285 @default.
• W4295779301 hasConcept C159047783 @default.
• W4295779301 hasConcept C167135981 @default.
• W4295779301 hasConcept C17923572 @default.
• W4295779301 hasConcept C201903717 @default.
• W4295779301 hasConcept C207103383 @default.
• W4295779301 hasConcept C2779134260 @default.
• W4295779301 hasConcept C2779298103 @default.
• W4295779301 hasConcept C2908647359 @default.
• W4295779301 hasConcept C2993143319 @default.
• W4295779301 hasConcept C3008058167 @default.
• W4295779301 hasConcept C3013748606 @default.
• W4295779301 hasConcept C44249647 @default.
• W4295779301 hasConcept C524204448 @default.
• W4295779301 hasConcept C61511704 @default.
• W4295779301 hasConcept C71924100 @default.
• W4295779301 hasConcept C72563966 @default.
• W4295779301 hasConcept C77350462 @default.
• W4295779301 hasConcept C99454951 @default.
• W4295779301 hasConceptScore W4295779301C120665830 @default.
• W4295779301 hasConceptScore W4295779301C121332964 @default.
• W4295779301 hasConceptScore W4295779301C126322002 @default.
• W4295779301 hasConceptScore W4295779301C142462285 @default.
• W4295779301 hasConceptScore W4295779301C159047783 @default.
• W4295779301 hasConceptScore W4295779301C167135981 @default.
• W4295779301 hasConceptScore W4295779301C17923572 @default.
• W4295779301 hasConceptScore W4295779301C201903717 @default.
• W4295779301 hasConceptScore W4295779301C207103383 @default.
• W4295779301 hasConceptScore W4295779301C2779134260 @default.
• W4295779301 hasConceptScore W4295779301C2779298103 @default.
• W4295779301 hasConceptScore W4295779301C2908647359 @default.
• W4295779301 hasConceptScore W4295779301C2993143319 @default.
• W4295779301 hasConceptScore W4295779301C3008058167 @default.
• W4295779301 hasConceptScore W4295779301C3013748606 @default.
• W4295779301 hasConceptScore W4295779301C44249647 @default.
• W4295779301 hasConceptScore W4295779301C524204448 @default.
• W4295779301 hasConceptScore W4295779301C61511704 @default.

• next